newsfilter
← Latest News
GlobeNewswire·

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

  • Chemomab Therapeutics will present new clinical data from the nebokitug Phase 2 SPRING trial open label extension at the AASLD The Liver Meeting on November 10, 2025.
  • Three presentations have been designated as Posters of Distinction.
  • Treatment with nebokitug demonstrated favorable safety & consistent improvements in key inflammatory & fibrotic biomarkers over up to 48 weeks.
  • Fifty of 54 eligible patients who completed the 15-week double-blind portion elected to participate in the open label extension for up to 33 additional weeks of treatment.
  • Sustained improvements were observed in the ELF score & liver stiffness measurements, particularly in patients with moderate/advanced disease receiving the 20mg/kg dose.
  • Nebokitug treatment led to dose-dependent reductions in serum macrophage-related proteins & increased expression of Macrophage Stimulating 1 (MST1).
  • Increases in MST1 were associated with greater reductions in liver stiffness & served as a downstream marker of CCL24 blockade.
  • Results support the evaluation of nebokitug 20mg/kg in a future Phase 3 pivotal trial based on a clinical event primary endpoint.
  • Nebokitug has received FDA & EMA Orphan Drug designations & FDA Fast Track designation for the treatment of primary sclerosing cholangitis (PSC).